Incyte Corporation (INCY)
Here's Why Incyte (INCY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disorder therapies.
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the matter.
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Here's Why Incyte (INCY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event.
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Inside Incyte's $120 Million AI For Drug Development Deal
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Incyte NASDAQ: INCY President and CEO Bill Meury said the company's post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology.
